Review top news and interview highlights from the week ending May 13, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Caribou will present the initial data at the upcoming European Hematology Association (EHA) meeting in June.
The trial was set to begin patient dosing in the first half of this year.
The cell therapy is the first to come out of the company’s proprietary ARC-SparX platform.
Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial with solid tumors, presented recently at the 2022 AACR Annual Meeting.
The locally injected gene therapy product is the subject of an ongoing phase 2a clinical trial.